Moustakli Efthalia, Potiris Anastasios, Zikopoulos Athanasios, Galani Apostolia, Kechagias Konstantinos, Karampas Grigorios, Anagnostaki Ismini, Christodoulaki Chrysi, Gerede Angeliki, Christopoulos Panagiotis, Thomakos Nikolaos, Stavros Sofoklis
Laboratory of Medical Genetics, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece.
Third Department of Obstetrics and Gynecology, University General Hospital "ATTIKON", Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece.
Cancers (Basel). 2025 Jul 11;17(14):2315. doi: 10.3390/cancers17142315.
Ovarian cancer remains one of the most lethal gynecological malignancies, primarily due to its late diagnosis and limited prospects for successful treatment. MiRNAs have been shown to be important post-transcriptional regulators in a variety of cancer-related pathways in recent years. One of the principal mechanisms underlying the motility, invasiveness, and metastatic potential of ovarian cancer cells is the microRNA-mediated regulation of ABPs. As integral components of the cytoskeletal network, ABPs participate in dynamic cellular processes such as migration, adhesion, and invasion, and are critically involved in tumor development and progression. Recent data indicate that some miRNAs affect ABP expression and activity, which in turn affects cytoskeletal remodeling and, ultimately, tumor cell behavior. The role of miRNAs in cancer development is inherently complex due to their ability to function as both tumor suppressors and oncogenes, depending on the molecular context. Key ABPs that are targeted by particular miRNAs are discussed in terms of their clinical relevance, including their potential utility as diagnostic biomarkers or therapeutic targets. A deeper understanding of these regulatory pathways may offer new opportunities for early detection and personalized treatment strategies. In this narrative review, the current knowledge of how miRNAs affect ABP expression and function, and how this interaction contributes to the development and progression of ovarian cancer, is compiled.
卵巢癌仍然是最致命的妇科恶性肿瘤之一，主要原因是其诊断较晚且成功治疗的前景有限。近年来，微小RNA（miRNAs）已被证明是多种癌症相关途径中重要的转录后调节因子。卵巢癌细胞的运动性、侵袭性和转移潜能的主要潜在机制之一是微小RNA介导的肌动蛋白结合蛋白（ABPs）调节。作为细胞骨架网络的组成部分，ABPs参与细胞迁移、黏附、侵袭等动态细胞过程，并在肿瘤发生发展中起关键作用。最近的数据表明，一些miRNAs影响ABP的表达和活性，进而影响细胞骨架重塑，最终影响肿瘤细胞行为。由于miRNAs根据分子背景既可以作为肿瘤抑制因子又可以作为癌基因发挥作用，其在癌症发生发展中的作用本质上是复杂的。本文讨论了特定miRNAs靶向的关键ABPs的临床相关性，包括它们作为诊断生物标志物或治疗靶点的潜在用途。对这些调节途径的更深入理解可能为早期检测和个性化治疗策略提供新的机会。在这篇叙述性综述中，汇总了目前关于miRNAs如何影响ABP表达和功能，以及这种相互作用如何促进卵巢癌发生发展的知识。
